14 citations
,
December 2010 in “Seminars in Oncology” Rare adrenal cancers that secrete androgens or estrogens have a poor prognosis and are treated primarily with surgery.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Oral minoxidil boosts hair growth and reduces shedding in androgenetic alopecia.
8 citations
,
January 2020 in “Evidence-based Complementary and Alternative Medicine” Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
2 citations
,
March 2005 in “Cancer biology & therapy” Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.
1 citations
,
April 2020 in “Journal of the Endocrine Society” Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
147 citations
,
October 2021 in “Cancer Communications” RC48 shows promise for treating certain advanced cancers, but more research is needed.
15 citations
,
January 2019 in “Journal of the Formosan Medical Association” Adalimumab helped control a child's severe eye disease when other treatments failed.
April 2024 in “Canadian Journal of Ophthalmology” A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.
September 2013 in “Oncology Times” Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.
October 2025 in “Australasian Journal of Dermatology” Bimekizumab effectively treated a man's chronic beard hair loss.
6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
1 citations
,
June 2018 in “Dermatologic Surgery” 42 citations
,
January 2008 in “Clinical colorectal cancer” Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.
March 2023 in “International Journal of Trichology” A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
2 citations
,
November 2025 in “Pharmacology Research & Perspectives” Avacopan may cause unexpected side effects, so early monitoring is important.
16 citations
,
August 2011 in “Annals of Allergy Asthma & Immunology” A woman with severe angioedema improved significantly after treatment with rituximab.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
April 2018 in “Journal of Investigative Dermatology” BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
4 citations
,
February 2019 in “Revista da Associação Médica Brasileira” FOLFOX6 chemotherapy effectively reduces VEGF levels and improves quality of life in advanced colorectal cancer patients.
September 2024 in “Current Oncology” Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.
22 citations
,
November 2005 in “BMC Cancer” Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.
26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
93 citations
,
May 2010 in “European Journal of Cancer” BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
August 2024 in “Dermatology and Therapy” Vorasidenib can cause unusual hair growth.
1 citations
,
March 2023 in “Medicine” The combination therapy is effective and well-tolerated for treating esophageal cancer.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.